Topoisomerases: A Biochemical Overview

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 39: Line 39:
The secondary structure consists of right-handed alpha helices and antiparallel beta strands, which makes up beta sheets. The enzyme consists of 11 alpha helices and 12 beta strands. The clustering of beta sheets in this particular structure of TOP1 creates 3 <scene name='91/919047/B_sheets_highlights/1'>beta sheets</scene> (highlighted in green) [8].
The secondary structure consists of right-handed alpha helices and antiparallel beta strands, which makes up beta sheets. The enzyme consists of 11 alpha helices and 12 beta strands. The clustering of beta sheets in this particular structure of TOP1 creates 3 <scene name='91/919047/B_sheets_highlights/1'>beta sheets</scene> (highlighted in green) [8].
-
The oligomeric state of the quaternary structure is <scene name='91/919047/Space_filling_model/2'>heterotetrameric</scene>. There is no symmetry in this particular enzyme, due to the presence of various distinct subunits [9].
+
The oligomeric state of the quaternary structure is <scene name='91/919047/Space_filling_model/2'>heteromonomeric</scene>. There is no symmetry in this particular enzyme, due to the presence of various distinct subunits [9].
The tertiary structure consists of several motifs and domains. The motifs present are alpha bundles, alpha non-bundles, beta rolls, and beta ribbons. The domain consists of five residues of tyrosine and is a loop-like shape. This loop serves as the <scene name='91/919047/Active_site_tyr_723/1'>active site</scene> (highlighted in purple) for the change in conformation, which allows for DNA helices entry [10].
The tertiary structure consists of several motifs and domains. The motifs present are alpha bundles, alpha non-bundles, beta rolls, and beta ribbons. The domain consists of five residues of tyrosine and is a loop-like shape. This loop serves as the <scene name='91/919047/Active_site_tyr_723/1'>active site</scene> (highlighted in purple) for the change in conformation, which allows for DNA helices entry [10].

Revision as of 18:36, 18 April 2023

This Sandbox is Reserved from August 30, 2022 through May 31, 2023 for use in the course Biochemistry I taught by Kimberly Lane at the Radford University, Radford, VA, USA. This reservation includes Sandbox Reserved 1730 through Sandbox Reserved 1749.
To get started:
  • Click the edit this page tab at the top. Click on Show preview and then Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Topoisomerase

TOP1 stabilizing DNA helix" (PDB entry 1a35)

Drag the structure with the mouse to rotate


References

1. Natassja G. Bush, Katherine Evans-Roberts, Anthony Maxwell. DNA Topoisomerases. EcoSal Plus (2015), Volume 6, Number 2, Domain: Synthesis and Processing of Macromolecules.

2. Vos, Seychelle M. Tretter, Elsa M. Schmidt, Bryan H. Berger, James M. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell Biol. (2011), 12, 12: 827-841.

3. Takahashi DT, Gadelle D, Agama K, Kiselev E, Zhang H, Yab E, Petrella S, Forterre P, Pommier Y, Mayer C. Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states. Nat. Commun. (2022), 13: 59.

4. Min Li, Yilun Liu. Topoisomerase I in Human Disease Pathogenesis and Treatments. GPB. (2016), 14, 3: 166-171.

5. Benjamin D. Bax, Garib Murshudov, Anthony Maxwell, Thomas Germe. DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion. J. Mol. Biol. (2019), 431, 18: 3427-3449.

6. Seungmin Han, Kwang Suk Lim, Brody J. Blackburn, Jina Yun, Charles W. Putnam, David A. Bull, Young-Wool Won. The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates. Pharmaceutics (2022), 14, 8: 1707-1707.

7. Mei Hong, Ming-Qiang Ren, Jeane Silva, Ananya Paul, W. David Wilson, Carsten Schroeder, Paul Weinberger, John Janik, Zhonglin Hao. YM155 Inhibits Topoisomerase Function. Anticancer Drugs (2017) 28(2): 142-152.

8. Nichols, M.D., DeAngelis, K., Keck, J.L. and Berger, J.M. Structure and function of an archaeal topoisomerase VI subunit with homology to the meiotic recombination factor Spo11. EMBO J. (1999), 18: 6177-6188.

9. Diane T. Takahashi, Daniele Gadelle, Keli Agama, Evgeny Kiselev, Hongliang Zhang, Emilie Yab, Stephanie Petrella, Patrick Forterre, Yves Pommier, Claudine Mayer. Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states. Nat. Commun. (2022), 13, 59.

10. James J. Champoux. DNA TOPOISOMERASES: Structure, Function, and Mechanism. Annu. Rev. (2001), 70:369–413.

Proteopedia Page Contributors and Editors (what is this?)

Jamison Reddy, Hunter Rogers, Matt Hineline, OCA

Personal tools